11 Facts About Testosterone Therapy for Women in Menopause
So many women come to this topic feeling vaguely embarrassed — like asking about testosterone makes them seem like they're trying to be someone they're not. That reaction is completely understandable given how this hormone has been framed as exclusively male for decades. The truth is far less dramatic and far more useful than the mythology around it.
Learn more about Rose →Women produce testosterone naturally — and always have
Testosterone is not a foreign or male-only hormone. Women produce it in the ovaries and adrenal glands throughout their lives, and it plays a role in bone density, muscle mass, mood, cognitive function, and sexual desire. Levels begin declining gradually from the mid-20s onward, with a more noticeable drop during the perimenopause and postmenopause transition.
Testosterone is prescribed off-label for women almost everywhere
No testosterone product is currently licensed specifically for women in most countries, including the US and UK — meaning clinicians who prescribe it are doing so off-label, using formulations designed for men at much lower doses. This isn't fringe medicine: major menopause societies including the British Menopause Society and the Menopause Society (formerly NAMS) formally support its use for hypoactive sexual desire disorder (HSDD) in postmenopausal women. Off-label does not mean unsafe or experimental.
Low sexual desire is the most evidence-backed reason to consider it
The strongest and most consistent body of research supports testosterone therapy specifically for hypoactive sexual desire disorder — a persistent, distressing reduction in sexual desire not explained by another cause. Multiple randomized controlled trials show that low-dose testosterone significantly improves desire, arousal, and satisfaction compared to placebo in postmenopausal women. This is the indication where the evidence is clearest and the clinical guidance most aligned.
It may also help with energy, mood, and brain fog — but the evidence is less settled
Many women and clinicians report meaningful improvements in fatigue, low mood, and cognitive sharpness with testosterone therapy, but randomized trial data for these outcomes is thinner and less consistent than for sexual desire. This doesn't mean the effects aren't real — it may reflect the difficulty of measuring these outcomes rigorously, and observational data is generally supportive. Women considering testosterone for these reasons should do so with realistic expectations and ideally alongside other evidence-based interventions.
The doses used for women are a fraction of those used for men
When male testosterone formulations are used for women, the prescribed dose is typically one-tenth or less of a male dose — enough to restore levels to the normal physiological range for women, not to elevate them above it. This distinction matters because many fears about side effects (voice changes, body hair, aggression) are dose-dependent and arise when testosterone is used at supraphysiologic levels. Properly dosed and monitored therapy keeps levels within the female reference range.
Side effects are real but usually mild and reversible
At recommended doses, the most commonly reported side effects are acne and increased facial or body hair — both of which typically resolve if the dose is reduced or treatment is stopped. Irreversible virilizing effects such as voice deepening or clitoral enlargement are associated with significantly supraphysiologic doses and are not a realistic risk of properly managed therapy. Blood level monitoring is a standard part of responsible prescribing and helps catch dose issues early.
There is no convincing evidence that it increases breast cancer risk
One of the most common fears about testosterone therapy is that it will increase breast cancer risk — but current evidence does not support this concern at physiological doses. Some research suggests testosterone may actually have a protective effect on breast tissue, partly because it can be converted to estrogen but also through direct receptor action that may inhibit breast cell proliferation. Longer-term safety data is still accumulating, and women with existing breast cancer should discuss the evidence carefully with their oncologist.
Blood tests before and during treatment are standard practice
A responsible prescriber will measure baseline testosterone levels before starting therapy and recheck them after around 3–6 months to confirm levels are within the normal female range. Testing typically looks at total testosterone and, where possible, free testosterone, since it's the unbound fraction that is biologically active. Regular monitoring is not just bureaucratic box-ticking — it's the mechanism that keeps therapy safe and effective.
It is usually used alongside estrogen, not instead of it
Testosterone therapy for menopausal women is almost always considered as an add-on to estrogen-based HRT, not a standalone replacement for it. Estrogen addresses the broadest range of menopausal symptoms and has the strongest safety and efficacy record; testosterone is typically introduced when symptoms — particularly low libido — persist despite adequate estrogen therapy. Using testosterone alone without addressing estrogen deficiency often produces incomplete results.
Application method matters — gels and creams are the most common route for women
Because no female-specific product is licensed in most countries, testosterone for women is most commonly administered as a small amount of topical gel or cream applied to the skin, usually the inner thigh or lower abdomen. Pellets (implanted under the skin) are used in some clinical settings but deliver less controllable dosing and make it harder to adjust or stop treatment quickly. Injections, which are standard in male therapy, are rarely used for women because they produce very uneven hormone levels.
Access is improving, but significant prescriber knowledge gaps remain
Despite formal endorsement from leading menopause societies, many women are still told by their doctor that testosterone is not appropriate for women, or that it doesn't exist as a treatment option — reflecting a training gap rather than the current state of evidence. Women who are curious about testosterone therapy are well within their rights to ask for a referral to a menopause specialist if their GP is not confident prescribing it. The evidence base and the clinical guidelines have moved faster than general medical education in this area.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.